Advancement continues for Nerium oleander compound
SAN ANTONIO—Phoenix Biotechnology Inc. has completed a Phase 1 trial of PBI-05204, its patented supercritical CO2 extract of Nerium oleander, in heavily pretreated cancer patients at the University of Texas M.D. Anderson Cancer Center, as well as an ex-vivo study against human tumor biopsies performed at Rational Therapeutics Inc. Preliminary analyses of its effects on tumor samples are “highly encouraging,” Phoenix Biotechnology notes on its website. The company is advancing this extract as a botanical drug, and while the company is developing it against malignant disease, it has also demonstrated effectiveness against stroke-mediated ischemic brain injury. To avoid the natural toxicity of the oleander, the plant’s leaves are broken into small pieces via a hands-free centrifugal force separation methodology, then put through extraction using a supercritical CO2 process, which enables the extraction of pharmacologically active ingredients that are nontoxic. Phoenix Biotechnology is now pursuing partnerships to advance work on the compound through Phase 2 clinical studies.